Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H6Cl5NO3 |
Molecular Weight | 401.457 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(NC(=O)C2=C(O)C(Cl)=CC(Cl)=C2Cl)C=C(Cl)C=C1Cl
InChI
InChIKey=JYWIYHUXVMAGLG-UHFFFAOYSA-N
InChI=1S/C13H6Cl5NO3/c14-4-1-6(16)11(20)8(2-4)19-13(22)9-10(18)5(15)3-7(17)12(9)21/h1-3,20-21H,(H,19,22)
DescriptionSources: https://goo.gl/hjMyxxCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25897961 | https://www.ncbi.nlm.nih.gov/pubmed/25771931
Sources: https://goo.gl/hjMyxx
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25897961 | https://www.ncbi.nlm.nih.gov/pubmed/25771931
Oxyclozanide is a salicylanilide anthelmintic, used for the treatment and control of fascioliasis in cattle, sheep, and goats. The mechanism of action of oxyclozanide is the uncoupling of oxidative phosphorylation in flukes. It is formulated as an oral drench containing oxyclozanide only or in combination with levamisole hydrochloride or oxfendazole or as a powder to be incorporated in the feed. The recommended doses are 10 to 15 mg oxyclozanide/kg BW for cattle and 15 mg oxyclozanide/kg BW for sheep and goats. The application was amended to exclude sheep milk and goat tissues and milk.
CNS Activity
Sources: https://goo.gl/hjMyxx
Curator's Comment: Oxyclozanide caused liver and brain toxicity at the highest tested doses.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25771931 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://goo.gl/hjMyxx |
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. | 2001 Jun 9 |
|
[Concentration in plasma and excretion in milk of lactating cows after oral administration of tribromsalan, oxyclozanide and bromofenofos]. | 2006 Dec |
|
Analysis of the IgG antibody response against Paramphistomidae trematoda in naturally infected cattle. Application to serological surveys. | 2006 Sep 10 |
|
The comparative efficacy of four anthelmintics against a natural acquired Fasciola hepatica infection in hill sheep flock in the west of Ireland. | 2009 Oct 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://goo.gl/hjMyxx
The recommended doses are 10 to 15 mg oxyclozanide/kg bw for cattle and 15 mg oxyclozanide/kg bw for sheep and goats
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897961
Oxyclozanide (5 mg/ml stock solution in DMSO) were tested by broth microdilution and disc diffusion assays in triplicate, adapted from established protocol. Broth microdilution was performed in triplicate in 96-well plates using Müller-Hinton broth (Becton Dickinson and Company, Franklin Lakes, NJ, USA). For testing MIC with daptomycin, the media was supplemented with CaCl2 at a final concentration of 50 μg/ml. The assay volume was 100 μl and twofold serial dilutions were carried out to get Oxyclozanide in the concentration range 0.0625–64 μg/ml. The bacterial concentration was adjusted to an initial OD600 of 0.03. After overnight incubation at 35°C, the absorbance was measured to determine antimicrobial activity. The minimum bactericidal concentration (MBC) was determined by plating 10 μl of culture volume from the MIC assay on Müller-Hinton agar and colony formation was examined after overnight incubation at 35°C. The lowest concentration at which colonies were not observed was regarded as the MBC.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QP52AG06
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16779
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
DTXSID50177312
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
m8327
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | Merck Index | ||
|
OXYCLOZANIDE
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
2159
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
CHEMBL2105450
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
SUB09561MIG
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
100000083282
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
1QS9G4876X
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
C66279
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
218-904-0
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY | |||
|
2277-92-1
Created by
admin on Fri Dec 15 15:28:14 UTC 2023 , Edited by admin on Fri Dec 15 15:28:14 UTC 2023
|
PRIMARY |
ACTIVE MOIETY